SISVEL
7.1.2016 17:46:21 CET | Business Wire | Press release
Sisvel, a global licensing company that has been dedicated to patent licensing since its foundation in 1982, has announced today that it is going beyond traditional patent licensing in how it acquires and monetizes patent portfolios and partners with IP players.
Sisvel is now offering its IP commercialization platform to anyone who wishes to gain greater value from Intellectual Property. This platform allows both IP Buyers and Sellers to use Sisvel’s proven network of partners, expertise in licensing and technical analysis – something no other entity now offers.
“IP buyers and sellers are in dire need to be directed by a competent player in the marketplace,” said Karel van Lelyveld, CEO of the Sisvel Group. “Sisvel has been active in this market for more than 30 years and we know what it takes to find the proverbial needle in a haystack. With our new IP Commercialization Platform we now provide easy and immediate access to buyers and sellers who want to transact assets. Our platform provides the simplicity and transparency needed to take back the market for those who develop innovative technologies and those who are seeking to get IP protection for innovative solutions”.
IP Commercialization Platform Features:
- Match for IP: Sisvel’s IP platform bridges buyer and seller requests and helps both parties achieve efficient solutions.
- Marketing IP Correctly: Sisvel’s team can help a company structure and optimize its Intellectual Property (IP) portfolio as well as identify the right assets to monetize.
- Finding the Proverbial Needle in a Haystack: Companies from around the world can now find specific IP assets in technical areas of interest, from selected sellers and pre-qualified portfolio opportunities.
“With Sisvel in the mix, there is no need to run around to ten or twenty different firms trying to buy access to the technologies you may need,” said Chuck Hausman, Vice President of Sisvel US.
Sisvel will formally unveil its new worldwide IP commercialization platform at CES 2016 with an announcement during a private reception on Thursday, January 7 from 4-6 p.m in the LVCC South Hall, Booth #1-20306. Sisvel’s management team will be available at the event to discuss the new platform’s benefits.
RSVP and further information:
Veronica Pugi veronica.pugi@sisvel.com
Sue
Ellen Schaming sschaming@hoogcomm.com
About Sisvel
Started in 1982 when Sisvel S.p.A. was founded
in Italy, the Sisvel Group has become a world leader in managing
intellectual property and maximizing the value of patent rights. The
Sisvel Group is global in scope and reach, with subsidiaries in Italy
(Sisvel and Sisvel Technology in None Torinese), the United States
(Sisvel US and Audio MPEG in Metropolitan Washington, DC), China (Sisvel
Hong Kong), Japan (Sisvel Japan in Tokyo), Germany (Sisvel Germany in
Stuttgart), Luxembourg (Sisvel International), and the United Kingdom
(Sisvel UK), with over one hundred professionals worldwide with
engineers, legal, and licensing expertise. Sisvel has a long history of
managing successful patent portfolios including those related to the
audio compression standards known as MP3 and MPEG Audio, and widespread
technologies such as OSD (On Screen Display), ATSS (Automatic Tuning &
Sorting System), and WSS (Wide Screen Signalling - for automatic
switching of television image formats). Sisvel currently operates patent
pools and joint licensing programs for the DVB-T, DVB-T2, LTE/LTE-A and
Wi-Fi standards, together with its Sisvel Wireless licensing program and
is in the process of creating a new licensing program for DVB-C2.
For additional information, please visit: www.sisvel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005959/en/
Contact:
Media Contact
Sisvel Group
Veronica Pugi, Tel: +
39 011 990 4114
Senior Communications Officer
veronica.pugi@sisvel.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom